# Chat, Check, Chart

## Tips and Tools: Assessment and Documentation

### Chat

3 prime questions
Personalized, open-ended questions to gather information on new and refill medication

<table>
<thead>
<tr>
<th>Purpose</th>
<th>New Medication</th>
<th>Refill Medication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>What did your prescriber tell you your medication is for?</td>
<td>This medication has many uses - what do you use it for?</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Direction</th>
<th>New Medication</th>
<th>Refill Medication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>How did your prescriber tell you to take the medication?</td>
<td>How have you been taking this medication?</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Monitoring</th>
<th>New Medication</th>
<th>Refill Medication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>What did your prescriber tell you to expect?</td>
<td>How is this medication working? What side effects have you had?</td>
</tr>
</tbody>
</table>
CHECK

4 questions
Evaluate the appropriateness of therapy*

I
Is therapy indicated?

E
Is therapy effective?

S
Is therapy safe?

U
Is the patient willing to use/adhere to therapy?

CHART

Efficient DAP
(eDAP: data, assessment, plan)**

NEW MEDICATION

Scenario: Atorvastatin 40 mg started for 53-year-old male patient, BA, who is a new patient
18/07/2015: Rx 235423

D: LDL 3.5 mmol/L, HDL 0.8 mmol/L, TG 2.0 mmol/L; not diabetic; 30 pack-year smoker; BP 134/89; Current Framingham 10-year CVD risk score >20%; No other medications or medical conditions.

A: Atorvastatin 40 mg indicated for primary hypercholesterolemia. Dose is effective for 35% reduction of baseline CVD risk. No contraindications or reasons for caution. Tx is appropriate.

P: RPh to discuss smoking cessation with patient at next refill in 1 month. BA to monitor for signs of myalgia. -RJP

REFILL MEDICATION

Scenario: Atorvastatin 40 mg started 1 month ago; BA reports no signs of myalgia
15/08/2015: Rx 233783

D: Atorvastatin 40 mg started 1 month ago; BA reports no signs of myalgia.

A: Atorvastatin 40 mg is appropriate; continue statin therapy for reduction of CVD risk. BA tolerating and adherent to therapy.

P: Patient to continue monitoring for myalgia. Consider smoking cessation again at next refill in 3 months. -RJP
